Pages that link to "Q28259053"
Jump to navigation
Jump to search
The following pages link to (Q28259053):
Displaying 50 items.
- Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1 (Q24534620) (← links)
- Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1 (Q24673555) (← links)
- Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry (Q28475912) (← links)
- Discovery of novel non-cyclam polynitrogenated CXCR4 coreceptor inhibitors (Q33356674) (← links)
- Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211). (Q33822912) (← links)
- Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents (Q34038718) (← links)
- Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity (Q34123595) (← links)
- The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. (Q34413630) (← links)
- CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection (Q34473072) (← links)
- Structural Analysis of Chemokine Receptor-Ligand Interactions (Q34550666) (← links)
- HIV entry inhibitors and their potential in HIV therapy (Q34595921) (← links)
- Regio- and stereoselective syntheses of the natural product CCR5 antagonist anibamine and its three olefin isomers (Q35400327) (← links)
- Development of anti-HIV peptides based on a viral capsid protein (Q36080284) (← links)
- Emerging drug targets for antiretroviral therapy (Q36237524) (← links)
- Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands (Q36296739) (← links)
- Oral CCR5 inhibitors: will they make it through? (Q36458354) (← links)
- The road map to oral bioavailability: an industrial perspective (Q36543116) (← links)
- Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition. (Q37071732) (← links)
- Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment. (Q37102101) (← links)
- Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain (Q37191794) (← links)
- Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc. (Q37421895) (← links)
- International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors (Q37432097) (← links)
- Chemokine receptor antagonists: part 2. (Q37481304) (← links)
- CCR5 antagonists: the answer to inflammatory disease? (Q37689783) (← links)
- Novel CCR5 antagonists for the treatment of HIV infection: a review of compounds patented in 2006 - 2008. (Q37697793) (← links)
- Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges (Q37780220) (← links)
- Inhibition of HIV‐1 Entry: Multiple Keys to Close the Door (Q37789226) (← links)
- Small molecule HIV entry inhibitors: Part I. Chemokine receptor antagonists: 2004 - 2010. (Q37827167) (← links)
- Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies (Q37834097) (← links)
- CCR5 inhibitors: emergence, success, and challenges (Q38005459) (← links)
- The successes and failures of HIV drug discovery (Q38014557) (← links)
- Targeting CCR5 for anti-HIV research (Q38229805) (← links)
- Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1. (Q38743504) (← links)
- CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV. (Q38803127) (← links)
- Discovery of INCB9471, a Potent, Selective, and Orally Bioavailable CCR5 Antagonist with Potent Anti-HIV-1 Activity (Q39158970) (← links)
- Interaction of small molecule inhibitors of HIV-1 entry with CCR5. (Q39444104) (← links)
- 4-Azatricyclo[5.2.2.02,6]undecane-3,5,8-triones as potential pharmacological agents. (Q39939436) (← links)
- Comparative docking study of anibamine as the first natural product CCR5 antagonist in CCR5 homology models. (Q40007908) (← links)
- Development of a Moloney murine leukemia virus-based pseudotype anti-HIV assay suitable for accurate and rapid evaluation of HIV entry inhibitors (Q40255176) (← links)
- Development of a novel dual CCR5-dependent and CXCR4-dependent cell-cell fusion assay system with inducible gp160 expression (Q40346497) (← links)
- Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). (Q40413724) (← links)
- Synthesis of (3) H, (2) H4 and (14) C-SCH 417690 (Vicriviroc). (Q40750016) (← links)
- A simple structure-based model for the prediction of HIV-1 co-receptor tropism (Q41827055) (← links)
- HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry (Q41895256) (← links)
- CCR5 pharmacology methodologies and associated applications. (Q46009371) (← links)
- Introduction. A brief history of AIDS (Q46169744) (← links)
- The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development (Q46489116) (← links)
- Novel screening systems for HIV-1 fusion mediated by two extra-virion heptad repeats of gp41. (Q46515258) (← links)
- The Expanding Therapeutic Perspective of CCR5 Blockade. (Q47800556) (← links)
- Complete Characterization of the 3D Properties of the CCR5 Antagonist Vicriviroc through DFT Calculations, NMR Spectroscopy, and X-ray Analysis (Q59671090) (← links)